These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29757301)

  • 61. Development of patient- and observer-reported outcome measures to assess COVID-19 signs and symptoms in children and adolescents.
    Romano C; Mayorga M; Ruiz-Guiñazú J; Trudel GC; Fehnel S; McQuarrie K; Chan EKH; Katz EG
    J Patient Rep Outcomes; 2023 Jan; 7(1):7. PubMed ID: 36701073
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Antistreptococcal interventions for guttate and chronic plaque psoriasis.
    Dupire G; Droitcourt C; Hughes C; Le Cleach L
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD011571. PubMed ID: 30835819
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis.
    Maruani A; Samimi M; Stembridge N; Abdel Hay R; Tavernier E; Hughes C; Le Cleach L
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD011541. PubMed ID: 30958563
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
    Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
    Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
    Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
    JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment Preferences in Young Adults with Moderate to Severe Psoriasis: A Qualitative Study from the Nordic Countries.
    Balieva FN; Catton L; Claréus BW; Danielsen K; Fierens F; Iversen L; Koulu L; Osmanecevic A; Pasternack R; Skov L
    Dermatol Ther (Heidelb); 2023 Aug; 13(8):1873-1887. PubMed ID: 37452929
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Moving cupping therapy for plaque psoriasis: A PRISMA-compliant study of 16 randomized controlled trials.
    Xing M; Ding X; Zhang J; Kuai L; Ru Y; Sun X; Ma T; Miao X; Liu L; Wang Y; Li B; Li X
    Medicine (Baltimore); 2020 Oct; 99(41):e22539. PubMed ID: 33031296
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.
    Mathias SD; Feldman SR; Crosby RD; Colwell HH; McQuarrie K; Han C
    J Dermatolog Treat; 2016 Aug; 27(4):322-7. PubMed ID: 26634943
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks.
    Reich A; Pinter A; Maul JT; Vender RB; Torres T; Brnabic A; Haustrup N; Reed C; Schuster C; Riedl E
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1825-1840. PubMed ID: 37147855
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials.
    McKenna SP; Cook SA; Whalley D; Doward LC; Richards HL; Griffiths CE; Van Assche D
    Br J Dermatol; 2003 Aug; 149(2):323-31. PubMed ID: 12932239
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Symptoms and markers of symptom severity in asthma--content validity of the asthma symptom diary.
    Globe G; Martin M; Schatz M; Wiklund I; Lin J; von Maltzahn R; Mattera MS
    Health Qual Life Outcomes; 2015 Feb; 13():21. PubMed ID: 25879643
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study.
    McMillan CV; Speight J; Relan A; Bellizzi L; Haase G; Cicardi M
    Patient; 2012; 5(2):113-26. PubMed ID: 22462765
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Development of an observer-reported outcome measure to capture the signs and impact of fever distress symptoms in infants and young children.
    Smith AB; Tselenti E; Kanabar D; Miles L
    Qual Life Res; 2022 May; 31(5):1573-1585. PubMed ID: 34993744
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Qualitative concept elicitation and cognitive debriefing interviews of symptoms, impacts and selected customized PROMIS
    Findley A; Middlehurst JM; Howse CA; Clifford MJ; Neill W; Tatlock S; Chen WH; Bracher MG; Patel DS
    J Patient Rep Outcomes; 2023 Apr; 7(1):39. PubMed ID: 37079188
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Assessing the Patient Experience of Hypoparathyroidism Symptoms: Development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom).
    Brod M; Waldman LT; Smith A; Karpf D
    Patient; 2020 Apr; 13(2):151-162. PubMed ID: 31552607
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity.
    Askanase AD; Daly RP; Okado M; Neville K; Pong A; Hanrahan LM; Merrill JT
    Health Qual Life Outcomes; 2019 Jun; 17(1):99. PubMed ID: 31174541
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Development and content validation of the Symptoms Evolution of COVID-19: a patient-reported electronic daily diary in clinical and real-world studies.
    Rofail D; McGale N; Im J; Rams A; Przydzial K; Mastey V; Sivapalasingam S; Podolanczuk AJ
    J Patient Rep Outcomes; 2022 May; 6(1):41. PubMed ID: 35507193
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Patients' Perspectives on the Impact of Genital Psoriasis: A Qualitative Study.
    Cather JC; Ryan C; Meeuwis K; Potts Bleakman AJ; Naegeli AN; Edson-Heredia E; Poon JL; Jones C; Wallace AN; Guenther L; Fretzin S
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):447-461. PubMed ID: 29076000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.